

Next Science receives CE mark approval for Bactisure

Sydney, Australia, Tuesday, 3 March 2020: Next Science Limited (ASX:NXS) is pleased to advise that it has received CE mark approval for Bactisure Surgical Lavage.

This allows Next Science to market and sell Bactisure in the European Union. Bactisure will be sold in Europe by Zimmer Biomet, our global distribution partner.

Managing Director, Judith Mitchell, commented: "Receipt of CE mark approval marks a major milestone for Next Science as we pursue our mission to heal patients and save lives worldwide by addressing the impacts of biofilms on human health."

Approved and authorised by the Chair of Next Science Limited.

Further information:

Judith Mitchell

Managing Director, Next Science Limited
Phone: +61 2 9375 7989
Email: investorqueries@nextscience.com

Michael Brown

Pegasus Advisory
Phone: +61 400 248 080
Email: mbrown@pegasusadvisory.com.au

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company's primary focus is on the development and commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology. Website: www.nextscience.com.